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Abstract: Vaccination is still the most efficient way to prevent an infection with influenza viruses.
Nevertheless, existing commercial vaccines face serious limitations such as availability during
epidemic outbreaks and their efficacy. Existing seasonal influenza vaccines mostly induce antibody
responses to the surface proteins of influenza viruses, which frequently change due to antigenic
shift and or drift, thus allowing influenza viruses to avoid neutralizing antibodies. Hence, influenza
vaccines need a yearly formulation to protect against new seasonal viruses. A broadly protective
or universal influenza vaccine must induce effective humoral as well as cellular immunity against
conserved influenza antigens, offer good protection against influenza pandemics, be safe, and
have a fast production platform. Nanotechnology has great potential to improve vaccine delivery,
immunogenicity, and host immune responses. As new strains of human epidemic influenza virus
strains could originate from poultry and swine viruses, development of a new universal influenza
vaccine will require the immune responses to be directed against viruses from different hosts.
This review discusses how the new vaccine platforms and nanoparticles can be beneficial in the
development of a broadly protective, universal influenza vaccine.
Keywords: seasonal influenza vaccine; universal influenza vaccine; humoral and cell-mediated
immunity; conserved viral proteins
1. Introduction
Influenza viruses possess single-stranded negative-sense viral RNA (vRNA) genomes belonging
to the Orthomyxoviridae family. Influenza A and B genomes each comprise eight segments, whilst
influenza C and D have seven segments that encode for at least 10 viral proteins [1]. Influenza A, B, and
C are able to infect humans, with influenza A and B being the most common circulating types. The virus
possesses a host cell-derived envelope membrane carrying the hemagglutinin (HA), the neuraminidase
(NA) glycoproteins, and the ion channel matrix protein 2 (M2). Inside the envelope is the matrix
protein layer consisting of the viral matrix protein 1 (M1) and the core viral ribonucleoprotein (vRNP)
complexes comprising the RNAs and the binding proteins, including the heterotrimeric polymerase
complex (PA, PB1, PB2) and multiple copies of nucleoproteins (NP) [2].
Influenza virus can cause seasonal or pandemic influenza infections [3]. In the United States, the
Centers for Disease Control and Prevention (CDC) estimates that influenza has caused 9.3 to 49 million
infections, 140,000 to 960,000 hospitalizations, and 12,000 to 79,000 deaths annually since 2010 [4].
Iuliano et al. (2018) estimated the global seasonal influenza-associated respiratory deaths annually to
be 291,243 to 645,832 [5]. These global influenza-associated mortality estimates are higher than those
previously reported by World Health Organization (WHO) (250,000 to 500,000) [6], which suggested
the previous estimates might have underestimated the disease burden. A total of 186 pediatric deaths
in the United States were recorded in the CDC report during the 2017–2018 influenza season and this
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number exceeded the previous 171 deaths reported during the 2012–2013 season. Approximately
80% of deaths in the United States happened in children who did not receive seasonal influenza
vaccinations [7].
Influenza pandemics caused by influenza A viruses can also emerge at unpredictable intervals
which could significantly increase morbidity and mortality when compared with seasonal influenza.
In 1918, 1957, 1968, and 2009, four influenza pandemics have occurred and claimed millions of lives [8].
Additionally, in recent years, influenza viruses from avian (H5N1, H7N9 and H9N2), swine (H1N1,
H1N2 and H3N2), and other zoonotic influenza viruses have caused more human infections and
mortalities compared to the past decades [9]. Nevertheless, there is a worry that viral shifts or drifts
might allow efficient transmission in humans and cause the next influenza pandemic [10].
Influenza vaccines have been in development since the early 1940s and still play a critical role
in providing protection. Current commercial influenza vaccines are mainly produced by egg-based
technologies and have several limitations, such as the supply of vaccine-quality eggs, vaccine
manufacturers cannot be flexible in the amount of doses being produced, moderate efficacy in certain
populations, time-consuming in the production process which could lead to vaccine shortages and lack
of cross-reactivity, especially during pandemic situations [11]. When the representative strains selected
for vaccine use are not well matched to the seasonal circulating influenza strains, the effectiveness of
the seasonal vaccines becomes very low [12].
Passaging the influenza viruses in eggs might also allow for the additional mutation(s) to occur
during manufacturing and could affect the efficiency of the seasonal vaccine [13]. Additionally,
some people are allergic to eggs and need to be vaccinated with egg-free influenza vaccines. There
are various types of influenza vaccines that are commercially available in the market. Most of the
clinically-available influenza vaccines could efficiently induce antibody responses against the globular
head of HA protein [14]. The effectiveness of seasonal influenza vaccine was reported to range between
10% and 60% [15]. In 2017, the overall efficacy of the seasonal influenza vaccine for Australia was
reported to be 33% [16] and for the United States was 36% [17].
Influenza viruses are subjected to continuing mutations each season and the current seasonal
influenza vaccination strategy keeps us at least one year behind the evolving virus [10]. The newly
emerged pandemic influenza virus could lead to making a matched monovalent vaccine that might
never be utilized, such as the H7N9 and H5N1 stockpiles which have since drifted or deteriorated [10].
Currently, there is a crucial need to develop more effective “broadly-reactive” or “universal” influenza
vaccine with high protection efficacy against new potential seasonal and pandemic strains.
Several studies have shown that humoral responses to HA and NA antigens could play an
essential role in host immunity against influenza due to antibodies, especially anti-HA could neutralize
the virus [18–20]. However, pre-existing CD8 T cell responses against the relatively conserved internal
antigens of the influenza virus are highly desirable as they could elicit immune responses towards
multiple viral strains, providing higher cross-protection capability in the absence of neutralizing
antibodies [21].
Advances in influenza biology, immunology, vaccinology, and bioinformatics have allowed the
contribution of new strategies to the rational design of universal influenza vaccines. Due to the
conserved antigen epitopes among distant virus strains, the development of a universal influenza
vaccine is theoretically possible. Here we review the commercial influenza vaccines, different arms of
the immune responses, and variable as well as conserved viral targets, and discuss recent scientific
progress in the development of virus-like particles (VLPs), nucleic acid (DNA and mRNA), and
peptide-based vaccines as potential next-generation universal influenza vaccines.
2. Commercial Influenza Vaccines
Strains used in licensed seasonal influenza vaccines are selected in February and September
following the influenza seasons in both the northern and southern hemispheres, respectively. The
WHO makes recommendations for next seasonal influenza vaccines based on the compositions of
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viruses from the surveillance, laboratory, and clinical observations [22]. Three classes of licensed
influenza vaccines are commercially available: Detergent-split inactivated influenza vaccine (IIV),
recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) (Table 1).
Inactivated vaccines (most frequently used for the prevention of influenza) include whole
inactivated virus vaccines (WIV), split virus vaccines, subunit vaccines, and virosomal influenza
vaccines. Typically, WIV production starts with influenza virus growth in 11-day-old pathogen-free
embryonic chicken eggs, followed by chemical inactivation with β-propiolactone or formaldehyde. The
allantoic fluid is harvested and clarified by centrifugation and purification. Instead of inactivation by
chemical agents, Furuya et al. (2010) advocatedγ-irradiation to inactive influenza A. They demonstrated
cross-protective immunity being induced by intranasal vaccination of mice with γ-irradiated influenza
A virus was mediated mainly by CD8 T cell responses [23,24].
Regarding the split virus vaccines, the virus is split before formulation and filtration, leading to
the removal of the detergent. Influenza subunit virus vaccines require further purification steps before
the final formulation to remove the nucleocapsids and lipids [22,25].
RIV and FluCelvax (IIV) are 100% egg-free influenza vaccines which were authorized for use in
the United States in 2013 and 2016, respectively, for people with egg allergies. The WHO has selected
the HA protein antigens from three influenza virus strains annually and each of the three recombinants
HAs were expressed through a viral host (baculovirus Autographa californica nuclear polyhedrosis
virus) in the insect cell line. The three individual HA proteins extracted from the cells in the presence of
detergent were further purified by column chromatography [26,27]. RIV has a shelf life slightly shorter
than most other injectable influenza vaccines currently available and expires within nine months from
the date of production [28].
LAIV for human application was developed in the 1960s independently by the United States and
Russia after serial passages of the influenza virus in eggs [22]. Reverse genetics was used to generate
multiple mutations in influenza viral genes to produce temperature-sensitive and cold-adapted LAIV.
The cold-adapted vaccine viruses could only replicate and grow when the temperature was below
25 ◦C and stopped growing when the temperature was above 37.8 ◦C [29]. FluMist, a cold-adapted
LAIV, was initially licensed in the United States in 2003 as an intranasal trivalent LAIV for use in people
aged two to 49. In 2012, it was replaced with the quadrivalent LAIV (LAIV4). The Advisory Committee
on Immunization Practices (ACIP) recommended that LAIV4 should not be used during the 2016–2017
and 2017–2018 influenza seasons due to poor efficacy against influenza A(H1N1)pdm09-like viruses
circulating in the United States during the 2013–2014 and 2015–2016 seasons [30]. Investigations into
the possible reason for this low efficacy against influenza A(H1N1)pdm09 demonstrated the replication
of viruses in human nasal epithelial cells was reduced when compared with pre-pandemic influenza
A(H1N1) LAIV viruses [31].
A new A(H1N1)pdm09 influenza virus such as the A/Slovenia/2903/2015 strain was included in
the LAIV4 formulation to replace the A/Bolivia/559/2013 strain for the 2017–2018 season. The ACIP
again suggested LAIV4 as a vaccine alternative for the 2018–2019 season on 21 February 2018 [30].
Regardless of the influenza vaccine strains or manufacturing platforms, most of the current
commercial influenza vaccines are generated by the growth of the selected viruses in embryonic
chicken eggs that depend on the continuous supply of chicken eggs and, in recent years, influenza
viruses have not been reported to grow well in eggs [22]. Forcing the selected viruses to grow
in embryonic chicken eggs frequently results in egg-adapted modifications associated with some
antigenic mismatches that could lead to changes in the HA head region and reduce the efficacy of
vaccine-generated antibody responses. This has been an issue for the H3N2 component of the vaccine
for several recent influenza seasons [22,32].
The general vaccine efficacy in the 2014–2015 influenza season was only 19% in the United States,
while in the 2017–2018 influenza season, during the most severe outbreak of an influenza epidemic, the
vaccine effectiveness was only 25% [15,33]. This was due to the emergence of the H3N2 virus which
was different from the vaccine strains present in the influenza vaccine formulation.
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Table 1. Categories of annual influenza vaccines approved by the Food and Drug Administration
(FDA).
Type of
Vaccine Virus Strain
Trade
Name Production Age
Immunological
Outcomes Route Ref.
IIV
Influenza A: H1N1 and
H3N2 virus/Influenza B:
Victoria and/or Yamagata
Fluzone Eggs 6–35 m
Ab immune
response IM [34]
Fluarix Eggs >6 m
Flucelvax MDCKcells >4 y
RIV
Contains the HA
ectodomain amino acid
sequence of cell-cultured
vaccine prototype viruses
suggested by WHO
Flublok
Recombinant-expression
in insect
cell line
>18 y Ab immuneresponse IM [35,36]
LAIV
Subtypes of H1N1 and
H3N2 (influenza A) and
one Influenza B
FluMist Eggs 2–49 y
Mucosal (nasal) IgA
Ab and strong
cell-mediated
immunity
IN [37–39]
Madin–Darby canine kidney (MDCK); intranasal (IN); intramuscular (IM); antibody (Ab); month (m); year (y);
inactivated influenza vaccine (IIV); hemagglutinin (HA); recombinant influenza vaccine (RIV); World Health
Organization (WHO); live attenuated influenza vaccine (LAIV)
3. Immune Responses Required for Universal Influenza Protection
Host immune responses against influenza virus are multifactorial and rapid mutations allow the
viruses to escape the immune responses generated after seasonal vaccination or infection. Therefore, a
promising universal influenza vaccine needs to stimulate B, CD8, and CD4 T cell responses against
various conserved proteins for efficient viral clearance, long-lasting immunity, and prevention of
reinfection (Figure 1).
The influenza HA and NA surface proteins are the major targets of humoral immune responses
and most of the current commercial seasonal influenza vaccines are targeting the globular head of
HA for neutralization. Rapid antigenic variations due to the accumulation of mutations within the
antibody-binding sites of HA and NA of circulating viruses have abrogated the affinity of some
antibodies to the viruses. Alternatively, the stem of HA is highly conserved when compared with the
globular head which made it a strong target for vaccine development to induce broadly neutralizing
antibodies and protective immune responses. Thus, targeting any conserved sites in the HA stem
could be a promising approach to the development of a new universal vaccine [40]. However, the
immunodominance of the head and steric hindrance of the stem could make it more difficult to
mount immune responses [38]. Thus, inducing broadly-neutralizing anti-stem antibodies remains a
challenge [41]. In addition to HA and NA humoral immune responses, some other conserved influenza
viral antigens could be recognized by the CD8 T cells and they are mostly found in the inner M1,
M2, NP, PA, and PB1 proteins [42]. Vaccines based on these antigens were heterosubtypic and were
able to induce broad immune responses as well as protection against viruses from different hosts in
animal models [43–45]. When there are no protective antibody responses to newly evolved influenza
viruses, T cells could provide heterosubtypic immunity to various influenza virus subtypes and even
unrelated viruses because of conserved peptide homology [46,47]. Therefore, the activated T cells
could provide the required immunological protection from infection with influenza. In the absence
of effective neutralizing antibodies, CD8 T cells were able to prevent the viral spread and conferred
high cross-protection against heterologous influenza viruses strains in both mice and humans [48–50].
Although CD4 T cell responses to infection with influenza and vaccine development have not received
as much attention as the CD8 T cells and humoral responses, their role is still important for host
protection against influenza [51]. In fact, depletion of CD4 T cells at the time of vaccination led to the
loss of all the protections; therefore, CD4 and CD8 T cells played important protective role during the
challenge. In addition, CD4 T cells demonstrated a necessary role during influenza vaccinations and
provided cross-protective anti-influenza immune responses.
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Pre-existing antibodies failed to neutralize various influenza viruses but CD4 memory T cells
were able to help in directing a faster antibody response via cytokine secretion in response to mutated
or immunologically novel viral antigens. There was limited virus shedding and disease severity,
possibly due to the direct lysis of infected epithelial cells [51–53]. Sheikh et al. (2016) demonstrated
cross-protection could be achieved by activating CD4 and CD8 T cells against highly conserved regions
of the influenza proteins [54].
A vaccine that could induce all of these immune responses against the influenza virus probably
would overcome most of the limitations of the current seasonal influenza vaccines and become a
universal influenza vaccine in the future.
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Figure 1. Antigens for universal influenza vaccine dev lopment. (A) Neutraliz ng antibodies ag inst
highly conserved hemagglutini (HA) (major protein of influenza virus) stem can provide broadly
protective immune responses and cross-protection. (B) Neutralizing antibodies against the globular head
of HA can prevent virus binding to sialic acid and prevent the conformati al change that leads to fusion.
(C) Anti-neuraminidase (NA) (second major protein of influenza virus) response targets the e zymatic
site to prevent virus entry, inhibit replicatio efficiency, decrease disease severity after infection and
cross-protection. (D) Anti-matrix protein 2 (M2) antibodies (third major protein of influenza virus)
provide a better cross-protective response due to the high conservation. Non-neutralizing Ab against
this domain mediates its mediates protection by antibody-dependent cell-mediated cytotoxicity. (E)
matrix protein 1 (M1) is an internal protein which is generally not exposed outside of the virus and
needs to be processed by major histocompatibility complex I (MHC I) for CD8 T cell antigen recognition.
(F) Highly conserved nucleoproteins (NP) viral proteins being used as a target to CD8 T cells to provide
better protection from several infections. (G) CD8 T cells recognize peptides derived from variable
(HA and NA) and highly conserved internal proteins (NP and M1) presented by MHC I at the surface
of antigen presenting cell (APC)/infected cells via their T cell receptor (TCR). Cytotoxic T lymphocytes
(CTL) release cytotoxic granules containing perforin and granzymes which lysis the infected cells. (H)
Memory CD4 T cells are required for early Ab and CD8 T cell recruitment responses.
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4. Potential Universal Vaccine Platforms
An ideal universal influenza vaccine will be effective against all influenza A and B viruses
regardless of any antigenic mutation(s) or HA and NA subtypes. The objective of this vaccine is to
induce cross-protective and long-lasting immune responses by stimulation of both arms of the immune
system. To design this type of vaccine, the highly conserved epitopes present in HA, NA, or M2 and
internal proteins such as NP and M1 should be targeted to induce cross-protective antibodies and T cells.
Development of a new universal influenza vaccine can be significantly facilitated by newly-developed
platform technologies such as multi-epitope, VLP, DNA, and mRNA-based vaccines, which will
be discussed. Advantages and disadvantages of whole peptide/multi-epitope (Figure 2A), DNA
(Figure 2B), mRNA (Figure 2C), and VLP (Figure 2D) vaccine platforms including their production
strategy, immunogenicity, and stability are discussed in Figure 2.
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4.1. Multi Epitope-Based Vaccine
The epitope-based approach focuses on conserved sequences of an antigen with the minimal
components that activate the lymphocytes: short peptides of eight to 10 amino acids for activation of
the CD8 T cells [55], 12 to 16 amino acids for activation of the CD4 T cells [56], and longer peptides of
up to 85 amino acids for activation of the B cells [57].
Recently, Rodriguez et al. (2018) developed a multi-peptide-based vaccine (Vacc-FLU) combining
one M2e peptide eliciting the humoral and three peptides representing the M2, NP, and a mixed
M2 and NP that were capable of eliciting the cell-mediated immune responses by using ISA51 as
an adjuvant in the murine model. Following two subcutaneous vaccinations, humoral and cellular
immune responses were induced to levels that could prevent symptomatic influenza infections and
provided partial protection in mice [58].
The stem region of the HA protein is considered as highly conserved when compared with the
globular head domain and could be considered as a promising target for a novel universal influenza
vaccine. Lu et al. (2017) identified a new mouse CD4 T cell epitope in the HA stem domain of the
pandemic H1N1 influenza virus. The intraperitoneal vaccination of mice with aluminum hydroxide gel
as an adjuvant induced significant polyfunctionality of splenocytes and degranulation. Furthermore,
immunized mice with the CD4 T cell epitope exhibited interindividual sharing of the CD4 TCRβ
clonotypes, and demonstrated partial protection against a lethal pandemic H1N1 challenge [59]. Two
influenza vaccines, the pentavalent Wyeth/IL-15/5Flu and the bivalent modified vaccinia virus Ankara
(MVA)/IL-15/HA/NA, were able to induce cross-neutralizing antibodies and conferred cross-clade
protection when challenged with the highly pathogenic avian influenza H5N1 virus of a different
clade [53].
4.1.1. Recombinant Epitope-Based Vaccine
The epitope-based Multimeric-001 (M-001) was firstly explored by Ben-Yedidia et al. [60] and
then developed by BiondVax Pharmaceuticals Ltd. (Ness Ziona, Israel). M-001 is a single recombinant
protein that consists of three repetitions of nine conserved linear epitopes from HA (four B and one CD4
T cell epitopes), NP (two CD8 T cell and one CD4 T cell epitopes), and M1 (one peptide containing both
B and CD8 T cell epitopes), which were derived from influenza A and B strains expressed in Escherichia
coli (E. coli). Preclinical and clinical studies of the M-001 confirmed the protection of mice against
different influenza strains by inducing both B and T cell-specific immune responses. As M-001 did not
contain any variable epitope of the HA of influenza, it was not able to induce specific hemagglutination
inhibition (HAI) antibodies and needed to be boosted with a seasonal or pandemic strain [61,62]. The
phase II clinical trial employed two priming doses of M-001, followed by a seasonal quadrivalent
inactivated influenza vaccine (IIV4). The 24-month clinical trial from April 2018 was conducted to
evaluate the safety, reactogenicity, and immunogenicity of the combined vaccines, which is still under
progress in three United States sites [63].
Another recombinant protein based on M2 ectodomain (M2e) was produced in E. coli by the fusion
of two tandem copies of consensus M2e sequences from human influenza A and two copies of M2e from
avian A/H5N1 viruses linked to the flagellin of Salmonella typhimurium. Intranasal immunization of
mice with the recombinant protein resulted in significant humoral and cellular responses and provided
comparable protection against lethal challenges with human H1N1/H3N2 and avian H5N1 influenza
A viruses [44]. Another recombinant protein, Flg-HA2-2-4M2e, was designed with a combination
of Salmonella typhimurium flagellin as a carrier with the conserved M2e and influenza A HA stalk
epitopes. Intranasal immunization of mice followed by two further boosts demonstrated that the
Flg-HA2-2-4M2e recombinant protein was highly immunogenic, and stimulated both systemic and
mucosal immune responses with the production of lung-resident virus-specific effector memory T
cells. The Flg-HA2-2-4M2e vaccine candidate was cross-protective and induced antiviral antibody
production against various phylogenetic groups of viruses [64]. Early-stage clinical studies have
demonstrated that the M2e-based vaccine was safe and was able to generate an anti-M2e antibody in
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up to 90% of healthy volunteers [65,66]. However, further clinical development of M2e as a universal
influenza vaccine did not progress well due to the rapid decline of anti-M2e IgG titers over time [67].
4.1.2. Recombinant Vectored Epitope-Based Vaccine
The conserved antigens of H1N1 and H5N1 influenza viruses from 1970 until 2010 were analyzed
for all hosts and countries by Huber et al. (2015) [68]. The influenza antigens NP, PB1, and M1 have
been selected as they have the largest amount of conserved regions, which also included a number of
recognized CD8 and CD4 T cell epitopes. Vaccination of mice and ferrets with the conserved B and T
cell epitope-based vaccine showed specific antibodies that could reduce viral loads in the lungs [68].
Some peptides present in the proteins of the influenza virus are conserved in humans and animals,
which could be expected to remain conserved even after genetic re-assortment. To develop a novel
universal influenza vaccine, it is vital to identify sequences of conserved antigens that include both
human and animal (bird and swine) B and T cell epitopes. Recently, Tutykhina et al. (2018) analyzed the
sequences of M2 and NP collected from influenza A over the last 100 years, with respect to mutations
in the sequences of recognized B and T cell epitopes, to determine conserved and evolutionarily
significant epitopes. Finally, consensus sequences of M2 (MSLLTEVETPIRNEWGCRCNDSSD and
SLLTEVETPIRNEWGCRCNDS) and NP (ILRGSVAHK and KTGGPIYRR) were found to be 100%
coincident with influenza viruses H1N1, H3N2, and H5N1 [69]. A recombinant adenoviral vectored
vaccine included nucleotide sequences corresponding to epitope-enriched amino acid sequences of M2
and NP, representing B and T cell epitopes of human, swine, and avian origin.
A single intranasal vaccination of mice with the recombinant Ad5-tet-M2NP vaccine induced robust
specific cellular responses to each of the encoded antigens and demonstrated an extremely wide-ranging
protection efficacy following challenge with five different influenza A viruses originating from three
different hosts. Eight months after immunization, high levels of effector memory CD44+CD62− T cells
against M2 and NP were found in splenocytes. This finding indicated that conserved B and T cell
epitopes might become one of the main approaches for developing a universal influenza vaccine.
Continual variations in the influenza virus antigen genes are the main cause of influenza outbreaks
and pose challenges for the development of a universal influenza vaccine. Consequently, epitope
predictions and utilization are of value in the design of highly conserved multi-epitope as recombinant
universal influenza vaccine [70,71].
4.2. DNA-Based Vaccine
Since the 1990s, efforts to develop influenza DNA vaccines have been on-going. Despite original
enthusiasm about protection in small animal models, studies in larger animal models have met with
relatively poor efficacy. Recent advances in DNA vaccine development showed that the poor efficacy
could be partially overcome by improving the selection of antigens and expression vectors, vaccine
delivery methods, routes of vaccination, targeting APC, co-delivery of adjuvants, and prime-boost
strategy [72,73].
To increase the effectiveness of the DNA vaccine and improve the immune responses, HA from
H7N1 was targeted to either major histocompatibility complex II (MHC II) molecules or chemokine
receptors 1, 3, and 5 that were displayed on APC. APC-targeted HA as a DNA vaccine was able to
considerably increase the level of neutralizing antibodies in sera and specific CD8 T cells, and protected
mice against a lethal H7N1 challenge [72].
In another study, Alexander et al. (2010) used fifty-two diverse influenza A sequences from strains
currently in circulation (H1N1, H3N2), strains from zoonotic infections of humans (H1N1, H5N1,
H7N2, H7N3, H7N7, H9N2) and past pandemic strains (H1N1, H2N2, H3N2) for CD4 T cell epitope
conservancy analysis. Vaccination with the conserved CD4 T cell influenza-specific epitopes was able
to elicit peptide-specific immune responses and T cell memory responses, which led to more rapid and
robust induction of HA-specific antibody responses. Peptide-specific immune responses protected
mice from lethal mouse-adapted H1N1 PR8 influenza virus challenge [74]. A polyvalent H5 DNA
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vaccine from H5N1 influenza viruses of A/Vietnam/1203/04, A/Anhui/1/2005, A/Indonesia/5/2005, and
A/Hongkong/156/97 was evaluated in New Zealand white (NZW) rabbits and the elicited antibodies
could provide broad protective humoral responses against various key H5N1 viruses [75].
Cynomolgus macaques were vaccinated with an influenza multi-antigen DNA vaccine containing
the HA, NP, and M2 proteins. Following a heterologous pandemic H1N1 strain challenge, immunized
animals showed faster virus clearance, significantly lower viral loads, elicited robust serum/mucosal
antibodies, and strong cross-reactive cellular immune responses, which could mediate significant
cross-protection [76].
Karlsson et al. (2018) vaccinated pigs twice with a polyvalent influenza DNA vaccine encoding
HA, M, NA, and NP on the dorsal side of the back by using a needle-free intradermal application of
liquid devices. Two weeks after the second immunization, all the animals were intranasally challenged
with the 2009 pandemic H1N1 and none of the vaccinated pigs became infected while all the control pigs
were infected. The results showed that a DNA vaccine could elicit HA and NA inhibiting antibodies
and cross-reactive neutralizing antibodies in a dose-dependent manner [77].
Recently, the first phase 1 clinical trial of a trivalent HA DNA vaccine against seasonal influenza was
conducted in the United States. Children from six to 17 years old received DNA vaccines intramuscularly
by the needle-free jet injector (Medical Technologies, Inc., Tualatin, OR, USA) and boosted with the split
virus 2012/2013 seasonal trivalent inactivated influenza vaccine (IIV3) approximately 18 weeks later. The
HA DNA vaccine prime-IIV3 boost was safe and well-tolerated compared to the prime-IIV3-boost-IIV3
regimen. Overall, humoral responses were comparable among groups although the increase of HAI
antibodies to A/California/07/2009 [A(H1N1)pdm09] was considerably higher after vaccination with the
HA DNA-IIV3 when compared to the IIV3-IIV3 [78]. After more than two decades of research, the first
commercial DNA vaccine against the highly pathogenic avian H5N1 in chickens has been provisionally
approved in 2017 by the United States Department of Agriculture (USDA) [79]. Successful control of
influenza can only be achieved through more in depth understanding of the inter-relationships between
animal and human influenza vaccines. This could lead to the design of a universal influenza vaccine.
Although a DNA-based vaccine against influenza is a flexible platform with long-term persistence
and cross-protective efficacy in preclinical challenge models, it has yet to show potency in human
clinical trials.
4.3. mRNA-Based Vaccines
mRNA vaccines are comprised of antigen-encoding genes whereby, after administration into host
cells, the RNA is translated into proteins that could elicit protective immunity against the infection.
Unlike DNA vaccines that need to enter into the cell nucleus, mRNA-based vaccines are translated in
the cytoplasm directly [80]. Although mRNA-based vaccines are very promising, there are limitations
associated with delivery and stability issues. Currently, two types of mRNA-based vaccines are being
created: the self-amplifying mRNA and the conventional non-amplifying mRNA [81].
The self-amplifying mRNA is capable of self-replication by RNA-dependent RNA polymerase,
producing various copies of the antigen-encoding mRNA, and expressing high levels of the heterologous
genes in the host cytoplasm. Conventional mRNA vaccines contain an open reading frame for the
target antigen, which is flanked by untranslated regions, and have a terminal poly(A) tail, which drives
transient antigen expression after transfection [82].
Magini et al. (2016) demonstrated immunization of mice with self-amplifying mRNA expressing
conserved internal influenza NP and M1 antigens, delivered individually or in conjugation with lipid
nanoparticles (LNanoPs), was able to induce strong polyfunctional CD4 T cells as well as central and
effector memory CD4 and CD8 T cells. The co-administration of self-amplifying mRNA-encoding
NP and M1 antigens along with the monovalent inactivated influenza vaccine (MIIV) could induce,
simultaneously, HA, NP, and M1-specific T cells, HA-specific neutralizing antibodies, and also improved
MIIV efficiency against a heterologous challenge [83].
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The timing of the production and availability of influenza vaccines is essential for an effective
response to new seasonal influenza outbreaks. It could take at least six months to formulate a new
FDA-approved pandemic influenza vaccine that could leave the population without any protection [84].
In 2009, after the disease peaked, the seasonal influenza vaccine became available and this has motivated
the development of a rapid vaccine that is important to protect against newly evolved strains. Hekelen
et al. (2013) developed the self-amplifying mRNA expressing the H7 vaccine against H7N9 only eight
days after the gene sequence became available. Therefore, the mRNA-based vaccine has the ability to
provide the technique for the fast development of an efficient next-generation influenza vaccine in
humans [85].
Lutz et al. (2017) showed a single intramuscular vaccination with the A/Netherlands/602/2009
(H1N1) HA-encoding mRNA formulated in LNanoPs, which induced >1:40 HAI titers in mice.
Administration of a second dose (three weeks after the prime vaccination) strongly boosted immune
responses and resulted in >1:160 HAI titers for up to one year that remained stable in all animals.
Fluad® is a commercial inactivated influenza vaccine containing the HA and NA of influenza virus
strains H1N1, H3N2, and B/Brisbane with MF59C.1 as the adjuvant. A single dose of the H3N2-HA
mRNA/LNanoP vaccine was effective to induce above 1:40 H3N2-HI titers and was comparable to
antibody titers induced by Fluad® [86].
Pardi et al. (2018) evaluated the effectiveness of a newly-developed influenza vaccine using
nucleoside-modified and purified mRNA-encoding full-length HA protein formulated in LNanoPs.
The results demonstrated that vaccination with HA mRNA-LNanoPs could induce strong specific
humoral immune responses against the conserved HA stalk domain in mice, ferrets, and rabbits.
The HA stalk specific antibodies protected mice against A/California/07/2009 H1N1,(homologous),
A/Puerto Rico/8/1934 H1N1 (heterologous), and H5N1 (heterosubtypic) influenza virus infection [87].
The self-amplifying mRNA expressing HA influenza virus when formulated with oil-in-water
cationic nanoemulsion showed immunogenic response in ferrets and facilitated containment of viral
replication in the upper respiratory tract. It was able to induce functional neutralizing antibodies
and HA-specific T cells in mice [88]. Furthermore, vaccination with an HA-encoded mRNA vaccine
conferred long-term immunity and elicited B and T cell-dependent protection in the newborn and
18-month-old mice, indicating that the mRNA vaccine was capable of reducing the burden of influenza
disease at the extremes of age [89].
mRNA-based vaccines against influenza provide a rapid, scalable, and cost-effective production
platform with no incorporation in the host DNA. It is also able to induce humoral and cellular immune
responses (Figure 2). The effective delivery of mRNA vaccines into the cytoplasm of host cells within
acceptable limits of tolerability is a key aspect to improve the vaccine efficacy [90].
4.4. Virus-Like Particles (VLPs)
VLPs are non-infectious particles obtained from the self-assembly of viral structural proteins
carrying viral antigens that could mimic the structure of live virus particles. Although most of
the commercial influenza vaccines are still based on the inactivated embryonic egg-grown virus,
advances in cell culture technologies involving plant, insect, and mammalian cells could provide
egg-independent manufacturing options to produce VLP vaccines [34]. In preclinical and clinical
studies, VLPs have been effective in their safety and efficacy. The VLPs were highly immunogenic
and could activate both cellular and humoral immune responses. Currently, two VLP-based vaccines
against hepatitis B virus (HBV) and human papillomavirus (HPV) are licensed for human use [91].
The influenza VLP vaccine derived from the A/Udorn 72 (H3N2) strain expressing HA and M1
generated in baculovirus was able to confer 100% protection in mice against the heterologous A/Hong
Kong/68 (H3N2) virus [92]. A vaccine comprising three tandem copies of M2e, NP, and the HBV core
(HBc) in VLPs could induce robust antibody and T cell immunity, improving the protection against
a lethal challenge with the pandemic 2009 H1N1 and the highly pathogenic avian influenza (HPAI)
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H5N1 virus in mice [93]. Most VLP-based influenza vaccines were developed comprising a single
antigen or a combination of HA, NA, and M antigens.
VLPs comprising a mixture of H1, H3, H5, or H7 HAs were produced using a recombinant
baculovirus expression system administered intranasally and then showed effective protection in mice
when challenged with influenza viruses expressing the 1918 H1, 1957 H2, avian H5, H6, H7, H10, and
H11 HA subtypes. Broad protection against various influenza A subtypes suggested that the VLP
platforms are promising and practical approaches for universal influenza vaccine development [94].
Several clinical trials in distinct populations (children, adults, and elderly) showed that significant
antibody titers induced by commercial egg-based seasonal influenza vaccine were detectable up to 18
months after the prime immunization. The performance of an insect cell-derived pandemic H1N1
2009 influenza VLP vaccine was successfully demonstrated in human clinical studies and showed the
persistence of antibodies up to 24 months after vaccination [95]. Subjects who were re-vaccinated with
a subsequent inactivated influenza virus vaccine induced the highest antibody titers to the pandemic
strains when compared to the unvaccinated subjects.
Luo et al. (2018) vaccinated mice with heterosubtypic influenza HA VLPs containing H1, H8, and
H13, or H3, H4, and H10 in various combinations using baculovirus expression systems. Multiple
antigenic variants with high genetic diversity could mimic the natural structure of the stalk domain and
generated broader humoral responses to confer complete protection against different homosubtypic
and heterosubtypic influenza viruses [96]. Although studies on influenza surface viral proteins have
shown promising results for developing universal vaccines, M2e as a naturally-conserved protein
has been included in VLPs and showed enhanced cross-protection against different influenza virus
subtypes like the H1N1, H3N2, and H5N1 [97,98].
In March 2013, Avian H7N9 influenza A virus was first recorded in China and the ability to
transmit from poultry to humans raised serious concerns about its pandemic potential. Intramuscular
vaccination of chickens and mice with VLPs comprising multi-antigens such as the HA, NA, and
M1 of avian influenza A (H7N9) expressed in baculovirus elicited HI serum titer and antibodies
against NA and M1 proteins [99]. In chickens, after two subcutaneous vaccinations with H5, H7, and
H9 VLPs using the baculovirus expression system, cross-reactive immune responses, and protection
were observed when challenged with heterologous HPAI H5N2, H7N3 and low pathogenic avian
influenza H9N2 [100]. In pigs, VLPs encoding HA, NA, and M1 proteins of H1N1pdm09 produced by
baculoviruses were found to elicit strong IgG (serum), IgA (mucosal), and viral neutralizing antibodies.
Following challenge with the pandemic H1N1 2009 strains, the vaccinated pigs were protected and
lung lesions were decreased; virus shedding and virus replication in the lungs were also inhibited [101].
In a human challenge study with the H3N2 virus, treatment with a monoclonal M2e specific
antibody was found to lead to a fast recovery. However, in phase I clinical study with the M2e VLP
vaccine, there was a rapid decline in anti-M2e IgG. New development of the M2e VLP vaccines could
involve the combination of a prime boost strategy with an HA-stalk based vaccine. Alternatively,
headless HA stalk domains could be incorporated and co-expressed [65]. The new generation of VLP
vaccines could involve incorporation of multiple conserved epitopes such as HA, NP, and M to confer
more cross-protection.
Plant-based VLP vaccines against influenza have proven to be immunogenic in both animals and
humans and have the potential to address several limitations of current vaccines including response
time and scalability in the event of a pandemic [102,103]. The Medicago VLP vaccine is a quadrivalent
influenza vaccine comprising recombinant H1, H3, and two B hemagglutinin proteins derived from
2018–2019 influenza virus strains. The phase III clinical trial of the Medicago VLP vaccine has been
in progress to assess the efficacy, safety, and immunogenicity in adults 65 years and older [104]. In
the study reported by Hodgins et al. (2019) a novel plant-derived VLP bearing HA could induce a
balanced humoral and cellular response in old mice [105]. Since the plant-based VLPs carried only
HA alone, it might not provide the protection to all clades of influenza. The recombinant baculovirus
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expression system in insect cells appeared to have high flexibility to produce universal VLP vaccines
containing multiple antigens (HA, NA, M1, and M2) and could provide broad protection.
5. Nanotechnology and Influenza Vaccine Development
Some promising results have been shown by epitope-based vaccines to induce protective
immune responses. The highly conserved epitopes across different influenza virus strains have
been extensively used to formulate universal influenza vaccines from either humans and animals.
Conserved antigen-based vaccines suffer from low immunogenicity and in most cases resulted in a weak
immune response with partial protection. These epitope-based vaccines require boosting and adjuvants
for robust and long-lasting immune responses. Due to the fast degradation of subunit vaccines in
the body, encapsulation and effective delivery are challenges for the universal influenza vaccine
development. Based on the recent developments in chemical engineering and biological understanding,
the new generation of NanoP-based vaccines can potentially overcome the low immunogenicity,
delivery, and controlled release and lead to enhancement of antigen presentation to achieve desired
immune responses.
NanoPs are compatible with a variety of immunogens and universal influenza vaccine development
has intensively used new approaches of nanotechnology. The morphological and structural properties
of NanoPs significantly improved the immunogenicity of conserved influenza viral antigens which
induced long-lasting immunity [106]. NanoPs could mimic the biophysical and biochemical
characteristics of virions and initiate strong signals to enhance innate immunity as well as eliciting
robust cellular and humoral immune responses with minimal cytotoxicity [107].
Aluminum-based mineral salts are the oldest and most widely used adjuvant in influenza vaccine
development [108]. Aluminum-based adjuvant may be sufficient to elicit antibody responses with
acceptable safety and efficiency, but they are weak immunostimulators of cellular immune responses
and are limited in their applications against intracellular pathogens vaccines [109]. NanoPs are
increasingly used as an adjuvant (nano-adjuvant) for vaccine development and formulations due to
their biocompatibility and flexibility in shape, size, and physicochemical properties. Nano-adjuvants
could improve the antigen delivery and presentation by professional APC and act as immunostimulators
that could activate innate and adaptive immunity. However, NanoPs have their own technical issues
and limitations such as loading of sufficient dose of the immunogen in the NanoPs, encapsulation of
the immunogen, and antigen denaturation during encapsulation [110].
Deng et al. (2018) generated a double-layered protein NanoP by desolvating tetrameric M2e
peptides into the protein nanoparticle cores and coating these cores by crosslinking headless HAs.
Intramuscular vaccinations of mice with protein nanoparticles were able to induce robust long-lasting
immune responses and completely protected mice against divergent influenza A viruses. These
findings demonstrated the significance of incorporation both headless HA stalk domain and M2e as a
potential universal influenza vaccine [111].
A combination of conserved B and T cell peptides of human influenza A virus H1N1 and
norovirus P particle-containing M2e (M2e-PP) from swine influenza viruses were encapsulated using
polylactic-co-glycolic acid (PLGA) NanoPs and administered intranasally. The results demonstrated
that PLGA NanoPs mediated the delivery of conserved peptides, induced the virus-specific cellular
responses in the lungs, reduced the viral titer of the heterologous influenza virus used in the challenge,
which resulted in robust prophylactic protection in pigs [112]. However, the encapsulated conserved
peptides with PLGA did not improve humoral immune responses (mucosal IgA and systemic antibodies)
in pigs. In another study, Dhakal et al. (2018) used liposome NanoPs as a carrier to incorporate ten
peptides representing the highly conserved T and B cell epitopes and delivered with monosodium
urate crystal as adjuvant. Intranasal immunization of pigs with liposomal delivery of conserved
peptide vaccines improved specific cellular and mucosal humoral immune responses [113].
Moreover, Bahl et al. (2017) showed that a single dose of the modified HA mRNA-based vaccine
of H7N9 encapsulated in LNanoPs could protect mice from a lethal influenza challenge as well
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as decreased lung viral titers in ferrets. In a human escalating-dose phase 1 H10N8 study, very
high seroconversion rates were observed. The results suggested that modified mRNA formulated
with LNanoPs could induce protective immunogenicity against influenza infection with acceptable
tolerability profiles [114]. Therefore, liposomes could encapsulate different antigens of influenza
viruses and protected humans, swine and mice from highly variant influenza serotypes. In another
approach, the M2e peptide of influenza virus was conjugated to gold NanoP and co-delivered with
CpG oligodeoxynucleotide as an adjuvant. Intranasal immunization of M2e-gold-CpG in mice induced
activation of B cells in the lungs and strong anti-M2e IgG subtype response in serum. The lethal
challenge of vaccinated mice with H1N1 (pandemic strain), H3N2, and H5N1 led to 100%, 92%, and
100% protection, respectively. Gold NanoPs as an intranasal vaccine carrier significantly increased
the immunogenicity of conserved M2e peptides in mice [115]. The H1-stabilized stem ferritin vaccine
was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious
Diseases (NIAID), which is composed of Helicobacter pylori non-heme ferritin assembled with the
influenza virus H1 HA insert to form a NanoP displaying eight HA-stabilized stem trimers from A/New
Caledonia/20/1999 (H1N1) influenza virus. The phase 1 clinical trial of this universal influenza vaccine
candidate is to examine the vaccine’s safety, tolerability, and ability to induce an immune response
in healthy volunteers aged 18 to 70 [116]. Wang et al. (2018) predicted that a universal influenza
vaccine would be available in eight to 10 years by incorporating layered protein nanoparticles for
effective delivery and controlled release technology, like dissolvable microneedle patch-based skin
vaccination [110].
6. Conclusions
Current seasonal influenza vaccines in use for humans and animals are lacking efficacy and can
only provide partial protection (10–60%) against influenza viruses. The worldwide rapid spread of
the 2009 influenza pandemic highlighted the urgent need for a cross-protective universal influenza
vaccine against different clades of viruses. Advanced vaccine platform technologies have enabled us
to achieve significant progress in the design and development of new universal influenza vaccines.
Due to the serious constraints of current egg-based influenza vaccine technology, a new generation
of egg-free influenza-based vaccines have been actively investigated. Among the newly-developed
vaccine technologies, genetic (RNA and DNA), recombinant multi-epitope-based peptide, or VLP
vaccines hold special promises. However, these vaccine platforms may suffer from limitations like
in vivo stability, delivery, bioavailability, and immunogenicity. The new generation of NanoP-based
vaccines showed great potential to address limitations like antigen availability, targeted delivery, and
immunogenicity, as well as antigen recognition by the APC. Moving forward, a universal influenza
vaccine should induce not only the HA and NA antibodies, but also T cell responses against highly
conserved viral antigens. Several new vaccine platforms which targeted conserved influenza antigens
like the stem of HA, NA, NP, and M2 have demonstrated broad cross-protection, heterosubtypic
immunity, and long-lasting protection in pre-clinical animal models. The most clinically-advanced
phase III vaccine candidates are the Biondvax’s M-001 and Medicago’s MT-2271 (VLP-based vaccine).
Some of the vaccines comprising conserved viral antigens like MVA-NP/M1, H1-stabilized stem
ferritin vaccine, and HA-stem as LAIV adjuvanted with AS03A are currently undergoing clinical
trials in humans. Although several of the novel vaccine technology platforms are promising for the
development of a universal influenza vaccine, it is obvious that none of the pre-clinical or early clinical
trials can mimic the real situation of a pandemic. Therefore, future studies might need to incorporate
either inactivated or IIV vaccines for boosting possible heterologous protection. In addition, for newly
emerging influenza viruses from pandemics, conserved T cell epitope predictive algorithms could
provide rational approaches for the design and development of a multi-epitope-based peptide or
expressed as a recombinant subunit vaccine.
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